respiratory syncytial virus

News

AZ, Sanofi build case for one-shot RSV antibody

A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respirat

News

Pfizer bulks up in RSV with $525m takeover of ReViral

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in

News

Trailing its RSV vaccine rivals, Bavarian Nordic cuts China ...

Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai's Nuance Pharma in a $225 million deal.

News

After GSK stumble, Pfizer moves forward with RSV vaccine

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant women, putting the company in pole position to bring a shot to market

News